Development of the clinical candidate PBD-C06, a humanized pGlu3-Aβ-specific antibody against Alzheimer’s disease with reduced complement activation

Abstract In clinical trials with early Alzheimer’s patients, administration of anti-amyloid antibodies reduced amyloid deposits, suggesting that immunotherapies may be promising disease-modifying interventions against Alzheimer’s disease (AD). Specific forms of amyloid beta (Aβ) peptides, for exampl...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Thore Hettmann, Stephen D. Gillies, Martin Kleinschmidt, Anke Piechotta, Koki Makioka, Cynthia A. Lemere, Stephan Schilling, Jens-Ulrich Rahfeld, Inge Lues
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2020
Materias:
R
Q
Acceso en línea:https://doaj.org/article/dab5d0faf6364197a4d53ba697df7975
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!